Benchmarking, Pharmaceutical and Profit and Loss

Transcript: Joel Tillinghast, Fidelity

Barry Ritholtz

DECEMBER 12, 2023

He has absolutely crushed his benchmark over that period. He’s crushed the Russell 2000, whatever benchmark you want to talk about. They announced a $640 million loss and ouch. So it leads to the question, what’s the secret to this longstanding outperformance against all benchmarks and, and all passive measures?

Benchmarking

Benchmarking Concentration Investments Profit and Loss

The Sugar Daddy Effect? Assessing Corporate venture capital, Sovereign funds and Green Energy!

Musings on Markets

OCTOBER 28, 2024

As companies mature, with business models delivering profits and reinvestment needs declining, it is not surprising the companies look outward, with acquisitions often entering the equation. This is, again, more likely to happen as companies age, and their internal R&D loses its punch.

Investments

Investments Profit and Loss Benchmarking Accounting

Corporate Finance Brief

Transcript: Joel Tillinghast, Fidelity

The Sugar Daddy Effect? Assessing Corporate venture capital, Sovereign funds and Green Energy!

Webinars

Stay Connected